Pharnext SA
Pharnext SA (ALPHA.PA) Stock Competitors & Peer Comparison
See (ALPHA.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALPHA.PA | €0.00 | +0.00% | 1.2K | -0.00 | -€200.00 | N/A |
| UCB.BR | €264.50 | -1.23% | 50.4B | 32.94 | €8.03 | +0.45% |
| ARGX.BR | €647.20 | +0.22% | 40.1B | 38.25 | €16.92 | N/A |
| TUB.BR | €219.50 | +0.69% | 9.8B | 104.52 | €2.10 | +0.41% |
| ABVX.PA | €101.40 | -0.59% | 8B | -20.99 | -€4.83 | N/A |
| GLPG.AS | €25.60 | -1.31% | 1.7B | 5.28 | €4.85 | N/A |
| NANO.PA | €27.40 | -5.35% | 1.3B | -54.80 | -€0.50 | N/A |
| PHARM.AS | €1.43 | -1.78% | 998.4M | -143.30 | -€0.01 | N/A |
| MEDCL.PA | €23.10 | -0.69% | 829.4M | -37.87 | -€0.61 | N/A |
| IVA.PA | €4.72 | +3.17% | 656.4M | -2.48 | -€1.90 | N/A |
Stock Comparison
ALPHA.PA vs UCB.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, UCB.BR has a market cap of 50.4B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while UCB.BR trades at €264.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas UCB.BR's P/E ratio is 32.94. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to UCB.BR's ROE of +0.15%. Regarding short-term risk, ALPHA.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check UCB.BR's competition here
ALPHA.PA vs ARGX.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ARGX.BR has a market cap of 40.1B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ARGX.BR trades at €647.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ARGX.BR's P/E ratio is 38.25. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ARGX.BR's ROE of +0.17%. Regarding short-term risk, ALPHA.PA is more volatile compared to ARGX.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ARGX.BR's competition here
ALPHA.PA vs TUB.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, TUB.BR has a market cap of 9.8B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while TUB.BR trades at €219.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas TUB.BR's P/E ratio is 104.52. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to TUB.BR's ROE of +0.05%. Regarding short-term risk, ALPHA.PA is more volatile compared to TUB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check TUB.BR's competition here
ALPHA.PA vs ABVX.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ABVX.PA has a market cap of 8B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ABVX.PA trades at €101.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ABVX.PA's P/E ratio is -20.99. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ABVX.PA's ROE of -1.65%. Regarding short-term risk, ALPHA.PA is more volatile compared to ABVX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ABVX.PA's competition here
ALPHA.PA vs GLPG.AS Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GLPG.AS has a market cap of 1.7B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GLPG.AS trades at €25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GLPG.AS's P/E ratio is 5.28. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GLPG.AS's ROE of +0.11%. Regarding short-term risk, ALPHA.PA is more volatile compared to GLPG.AS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check GLPG.AS's competition here
ALPHA.PA vs NANO.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, NANO.PA has a market cap of 1.3B. Regarding current trading prices, ALPHA.PA is priced at €0.00, while NANO.PA trades at €27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas NANO.PA's P/E ratio is -54.80. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to NANO.PA's ROE of +0.77%. Regarding short-term risk, ALPHA.PA is more volatile compared to NANO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check NANO.PA's competition here
ALPHA.PA vs PHARM.AS Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, PHARM.AS has a market cap of 998.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while PHARM.AS trades at €1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas PHARM.AS's P/E ratio is -143.30. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to PHARM.AS's ROE of +0.01%. Regarding short-term risk, ALPHA.PA is more volatile compared to PHARM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check PHARM.AS's competition here
ALPHA.PA vs MEDCL.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, MEDCL.PA has a market cap of 829.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while MEDCL.PA trades at €23.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas MEDCL.PA's P/E ratio is -37.87. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to MEDCL.PA's ROE of +0.85%. Regarding short-term risk, ALPHA.PA is more volatile compared to MEDCL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check MEDCL.PA's competition here
ALPHA.PA vs IVA.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, IVA.PA has a market cap of 656.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while IVA.PA trades at €4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas IVA.PA's P/E ratio is -2.48. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to IVA.PA's ROE of +5.36%. Regarding short-term risk, ALPHA.PA is more volatile compared to IVA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check IVA.PA's competition here
ALPHA.PA vs GTBP.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GTBP.PA has a market cap of 626.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GTBP.PA trades at €280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GTBP.PA's P/E ratio is -4.10. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GTBP.PA's ROE of -8.81%. Regarding short-term risk, ALPHA.PA is less volatile compared to GTBP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPHA.PA.Check GTBP.PA's competition here
ALPHA.PA vs DBV.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, DBV.PA has a market cap of 614.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while DBV.PA trades at €3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas DBV.PA's P/E ratio is -3.99. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to DBV.PA's ROE of -1.89%. Regarding short-term risk, ALPHA.PA is more volatile compared to DBV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check DBV.PA's competition here
ALPHA.PA vs VLA.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, VLA.PA has a market cap of 466.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while VLA.PA trades at €2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas VLA.PA's P/E ratio is -3.99. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to VLA.PA's ROE of -0.75%. Regarding short-term risk, ALPHA.PA is more volatile compared to VLA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check VLA.PA's competition here
ALPHA.PA vs GNFT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GNFT.PA has a market cap of 430.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GNFT.PA trades at €8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GNFT.PA's P/E ratio is -11.06. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GNFT.PA's ROE of -0.64%. Regarding short-term risk, ALPHA.PA is more volatile compared to GNFT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check GNFT.PA's competition here
ALPHA.PA vs ALCLS.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALCLS.PA has a market cap of 224.6M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALCLS.PA trades at €3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALCLS.PA's P/E ratio is -5.35. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALCLS.PA's ROE of -0.70%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALCLS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALCLS.PA's competition here
ALPHA.PA vs ORY.MC Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ORY.MC has a market cap of 220M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ORY.MC trades at €2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ORY.MC's P/E ratio is -93.00. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ORY.MC's ROE of -0.03%. Regarding short-term risk, ALPHA.PA is more volatile compared to ORY.MC. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ORY.MC's competition here
ALPHA.PA vs ONWD.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ONWD.BR has a market cap of 144.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ONWD.BR trades at €3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ONWD.BR's P/E ratio is -3.59. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ONWD.BR's ROE of -0.93%. Regarding short-term risk, ALPHA.PA is more volatile compared to ONWD.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ONWD.BR's competition here
ALPHA.PA vs HYL.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, HYL.BR has a market cap of 135.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while HYL.BR trades at €4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas HYL.BR's P/E ratio is -20.21. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to HYL.BR's ROE of -0.17%. Regarding short-term risk, ALPHA.PA is more volatile compared to HYL.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check HYL.BR's competition here
ALPHA.PA vs ABNX.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ABNX.PA has a market cap of 130.3M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ABNX.PA trades at €3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ABNX.PA's P/E ratio is -28.42. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ABNX.PA's ROE of -1.15%. Regarding short-term risk, ALPHA.PA is more volatile compared to ABNX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ABNX.PA's competition here
ALPHA.PA vs ALSEN.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALSEN.PA has a market cap of 127.9M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALSEN.PA trades at €0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALSEN.PA's P/E ratio is -4.18. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALSEN.PA's ROE of -0.58%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALSEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALSEN.PA's competition here
ALPHA.PA vs IPH.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, IPH.PA has a market cap of 108.9M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while IPH.PA trades at €1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas IPH.PA's P/E ratio is -2.11. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to IPH.PA's ROE of +5.94%. Regarding short-term risk, ALPHA.PA is more volatile compared to IPH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check IPH.PA's competition here
ALPHA.PA vs TNG.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, TNG.PA has a market cap of 106.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while TNG.PA trades at €0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas TNG.PA's P/E ratio is -2.85. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to TNG.PA's ROE of -0.64%. Regarding short-term risk, ALPHA.PA is more volatile compared to TNG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check TNG.PA's competition here
ALPHA.PA vs ADOC.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ADOC.PA has a market cap of 90.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ADOC.PA trades at €4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ADOC.PA's P/E ratio is -4.94. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ADOC.PA's ROE of +5.24%. Regarding short-term risk, ALPHA.PA is more volatile compared to ADOC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ADOC.PA's competition here
ALPHA.PA vs MAAT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, MAAT.PA has a market cap of 86.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while MAAT.PA trades at €5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas MAAT.PA's P/E ratio is -2.66. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to MAAT.PA's ROE of -3.34%. Regarding short-term risk, ALPHA.PA is more volatile compared to MAAT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check MAAT.PA's competition here
ALPHA.PA vs OSE.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, OSE.PA has a market cap of 73.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while OSE.PA trades at €3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas OSE.PA's P/E ratio is -13.71. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to OSE.PA's ROE of -0.61%. Regarding short-term risk, ALPHA.PA is more volatile compared to OSE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check OSE.PA's competition here
ALPHA.PA vs ERYP.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ERYP.PA has a market cap of 48.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ERYP.PA trades at €0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ERYP.PA's P/E ratio is -80.10. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ERYP.PA's ROE of -0.96%. Regarding short-term risk, ALPHA.PA is more volatile compared to ERYP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ERYP.PA's competition here
ALPHA.PA vs ALVIO.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALVIO.PA has a market cap of 42.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALVIO.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALVIO.PA's P/E ratio is -1.36. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALVIO.PA's ROE of +1.46%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALVIO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALVIO.PA's competition here
ALPHA.PA vs VVY.AS Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, VVY.AS has a market cap of 39.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while VVY.AS trades at €1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas VVY.AS's P/E ratio is -2.77. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to VVY.AS's ROE of -2.26%. Regarding short-term risk, ALPHA.PA is more volatile compared to VVY.AS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check VVY.AS's competition here
ALPHA.PA vs COX.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, COX.PA has a market cap of 29M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while COX.PA trades at €0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas COX.PA's P/E ratio is -0.46. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to COX.PA's ROE of -0.43%. Regarding short-term risk, ALPHA.PA is more volatile compared to COX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check COX.PA's competition here
ALPHA.PA vs ALVAL.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALVAL.PA has a market cap of 25.3M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALVAL.PA trades at €1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALVAL.PA's P/E ratio is -2.28. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALVAL.PA's ROE of -1.09%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALVAL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALVAL.PA's competition here
ALPHA.PA vs FALG.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, FALG.PA has a market cap of 24M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while FALG.PA trades at €0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas FALG.PA's P/E ratio is -2.33. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to FALG.PA's ROE of -0.39%. Regarding short-term risk, ALPHA.PA is more volatile compared to FALG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check FALG.PA's competition here
ALPHA.PA vs DMSIM.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, DMSIM.BR has a market cap of 23.1M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while DMSIM.BR trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas DMSIM.BR's P/E ratio is 0.09. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to DMSIM.BR's ROE of -0.57%. Regarding short-term risk, ALPHA.PA is more volatile compared to DMSIM.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check DMSIM.BR's competition here
ALPHA.PA vs ALGEN.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALGEN.PA has a market cap of 22.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALGEN.PA trades at €2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALGEN.PA's P/E ratio is 13.83. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALGEN.PA's ROE of +0.07%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALGEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALGEN.PA's competition here
ALPHA.PA vs ALDVI.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALDVI.PA has a market cap of 21.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALDVI.PA trades at €1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALDVI.PA's P/E ratio is -1.88. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALDVI.PA's ROE of +0.44%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALDVI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALDVI.PA's competition here
ALPHA.PA vs AELIS.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, AELIS.PA has a market cap of 17.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while AELIS.PA trades at €1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas AELIS.PA's P/E ratio is -2.17. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to AELIS.PA's ROE of -1.01%. Regarding short-term risk, ALPHA.PA is more volatile compared to AELIS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check AELIS.PA's competition here
ALPHA.PA vs ALPHE.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALPHE.PA has a market cap of 15.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALPHE.PA trades at €2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALPHE.PA's P/E ratio is -2.67. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALPHE.PA's ROE of -0.64%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALPHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALPHE.PA's competition here
ALPHA.PA vs SIGHT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, SIGHT.PA has a market cap of 15.3M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while SIGHT.PA trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas SIGHT.PA's P/E ratio is -0.68. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to SIGHT.PA's ROE of +0.42%. Regarding short-term risk, ALPHA.PA is more volatile compared to SIGHT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check SIGHT.PA's competition here
ALPHA.PA vs POXEL.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, POXEL.PA has a market cap of 15.1M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while POXEL.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas POXEL.PA's P/E ratio is -1.08. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to POXEL.PA's ROE of +0.23%. Regarding short-term risk, ALPHA.PA is more volatile compared to POXEL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check POXEL.PA's competition here
ALPHA.PA vs CYAD.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, CYAD.BR has a market cap of 14.3M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while CYAD.BR trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas CYAD.BR's P/E ratio is -0.22. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to CYAD.BR's ROE of +0.67%. Regarding short-term risk, ALPHA.PA is more volatile compared to CYAD.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check CYAD.BR's competition here
ALPHA.PA vs ALNFL.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALNFL.PA has a market cap of 13.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALNFL.PA trades at €1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALNFL.PA's P/E ratio is -3.79. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALNFL.PA's ROE of -2.25%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALNFL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALNFL.PA's competition here
ALPHA.PA vs BAI.AS Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, BAI.AS has a market cap of 11.2M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while BAI.AS trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas BAI.AS's P/E ratio is -0.13. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to BAI.AS's ROE of -0.51%. Regarding short-term risk, ALPHA.PA is more volatile compared to BAI.AS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check BAI.AS's competition here
ALPHA.PA vs ALVET.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALVET.PA has a market cap of 10M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALVET.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALVET.PA's P/E ratio is -0.17. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALVET.PA's ROE of -0.23%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALVET.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALVET.PA's competition here
ALPHA.PA vs APM.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, APM.PA has a market cap of 8.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while APM.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas APM.PA's P/E ratio is -0.71. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to APM.PA's ROE of -0.14%. Regarding short-term risk, ALPHA.PA is less volatile compared to APM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPHA.PA.Check APM.PA's competition here
ALPHA.PA vs ALPAT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALPAT.PA has a market cap of 8.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALPAT.PA trades at €7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALPAT.PA's P/E ratio is 9.01. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALPAT.PA's ROE of +0.11%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALPAT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALPAT.PA's competition here
ALPHA.PA vs ALTME.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALTME.PA has a market cap of 6.7M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALTME.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALTME.PA's P/E ratio is -1.42. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALTME.PA's ROE of -8.77%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALTME.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALTME.PA's competition here
ALPHA.PA vs ALQGC.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALQGC.PA has a market cap of 5M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALQGC.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALQGC.PA's P/E ratio is -0.09. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALQGC.PA's ROE of +8.81%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALQGC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALQGC.PA's competition here
ALPHA.PA vs LYS.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, LYS.PA has a market cap of 4.9M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while LYS.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas LYS.PA's P/E ratio is -0.64. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to LYS.PA's ROE of -11.30%. Regarding short-term risk, ALPHA.PA is more volatile compared to LYS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check LYS.PA's competition here
ALPHA.PA vs ALHYG.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALHYG.PA has a market cap of 3.9M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALHYG.PA trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALHYG.PA's P/E ratio is -0.26. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALHYG.PA's ROE of -6.80%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALHYG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALHYG.PA's competition here
ALPHA.PA vs ALACT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALACT.PA has a market cap of 3.9M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALACT.PA trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALACT.PA's P/E ratio is -0.22. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALACT.PA's ROE of +4.93%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALACT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALACT.PA's competition here
ALPHA.PA vs ALMDP.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALMDP.PA has a market cap of 1.8M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALMDP.PA trades at €0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALMDP.PA's P/E ratio is -0.59. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALMDP.PA's ROE of +1.42%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALMDP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALMDP.PA's competition here
ALPHA.PA vs BIOS.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, BIOS.BR has a market cap of 1.4M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while BIOS.BR trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas BIOS.BR's P/E ratio is -0.11. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to BIOS.BR's ROE of -1.64%. Regarding short-term risk, ALPHA.PA is more volatile compared to BIOS.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check BIOS.BR's competition here
ALPHA.PA vs ALINT.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALINT.PA has a market cap of 1.2M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALINT.PA trades at €0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALINT.PA's P/E ratio is -4.70. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALINT.PA's ROE of -1.48%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALINT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALINT.PA's competition here
ALPHA.PA vs ALDEI.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALDEI.PA has a market cap of 1.1M. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALDEI.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALDEI.PA's P/E ratio is -0.11. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALDEI.PA's ROE of +0.61%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALDEI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALDEI.PA's competition here
ALPHA.PA vs GNRO.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GNRO.PA has a market cap of 908.2K. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GNRO.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GNRO.PA's P/E ratio is -0.05. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GNRO.PA's ROE of +2.40%. Regarding short-term risk, ALPHA.PA is more volatile compared to GNRO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check GNRO.PA's competition here
ALPHA.PA vs OVXA.IR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, OVXA.IR has a market cap of 856.4K. Regarding current trading prices, ALPHA.PA is priced at €0.00, while OVXA.IR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas OVXA.IR's P/E ratio is -0.21. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to OVXA.IR's ROE of -0.93%. Regarding short-term risk, ALPHA.PA is more volatile compared to OVXA.IR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check OVXA.IR's competition here
ALPHA.PA vs ALBPS.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALBPS.PA has a market cap of 397.2K. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALBPS.PA trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALBPS.PA's P/E ratio is -0.05. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALBPS.PA's ROE of +0.92%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALBPS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALBPS.PA's competition here
ALPHA.PA vs OXUR.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, OXUR.BR has a market cap of 350.5K. Regarding current trading prices, ALPHA.PA is priced at €0.00, while OXUR.BR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas OXUR.BR's P/E ratio is N/A. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to OXUR.BR's ROE of -0.17%. Regarding short-term risk, ALPHA.PA is more volatile compared to OXUR.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check OXUR.BR's competition here
ALPHA.PA vs ALNEV.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALNEV.PA has a market cap of 238. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALNEV.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALNEV.PA's P/E ratio is N/A. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALNEV.PA's ROE of -1.06%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALNEV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALNEV.PA's competition here
ALPHA.PA vs GKTX.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GKTX.PA has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GKTX.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GKTX.PA's P/E ratio is -2.56. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GKTX.PA's ROE of -2.26%. Regarding short-term risk, ALPHA.PA is more volatile compared to GKTX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check GKTX.PA's competition here
ALPHA.PA vs ORPH.IR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ORPH.IR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ORPH.IR trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ORPH.IR's P/E ratio is N/A. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ORPH.IR's ROE of +0.27%. Regarding short-term risk, ALPHA.PA is more volatile compared to ORPH.IR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ORPH.IR's competition here
ALPHA.PA vs ACPH.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ACPH.BR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ACPH.BR trades at €0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ACPH.BR's P/E ratio is -1.40. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ACPH.BR's ROE of -1.55%. Regarding short-term risk, ALPHA.PA is more volatile compared to ACPH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ACPH.BR's competition here
ALPHA.PA vs ALNOX.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALNOX.PA has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALNOX.PA trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALNOX.PA's P/E ratio is -0.19. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALNOX.PA's ROE of -2.36%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALNOX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALNOX.PA's competition here
ALPHA.PA vs ALONC.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALONC.PA has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALONC.PA trades at €14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALONC.PA's P/E ratio is 63.25. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALONC.PA's ROE of -0.09%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALONC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALONC.PA's competition here
ALPHA.PA vs ALIMM.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ALIMM.BR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ALIMM.BR trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ALIMM.BR's P/E ratio is -2.23. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ALIMM.BR's ROE of -0.39%. Regarding short-term risk, ALPHA.PA is more volatile compared to ALIMM.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ALIMM.BR's competition here
ALPHA.PA vs ASIT.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ASIT.BR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ASIT.BR trades at €0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ASIT.BR's P/E ratio is -32.71. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ASIT.BR's ROE of +0.38%. Regarding short-term risk, ALPHA.PA is more volatile compared to ASIT.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ASIT.BR's competition here
ALPHA.PA vs GLPG.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, GLPG.BR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while GLPG.BR trades at €15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas GLPG.BR's P/E ratio is N/A. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to GLPG.BR's ROE of -0.10%. Regarding short-term risk, ALPHA.PA is more volatile compared to GLPG.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check GLPG.BR's competition here
ALPHA.PA vs BOTHE.BR Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, BOTHE.BR has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while BOTHE.BR trades at €0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas BOTHE.BR's P/E ratio is -0.38. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to BOTHE.BR's ROE of +2.97%. Regarding short-term risk, ALPHA.PA is more volatile compared to BOTHE.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check BOTHE.BR's competition here
ALPHA.PA vs ADVIC.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, ADVIC.PA has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while ADVIC.PA trades at €6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas ADVIC.PA's P/E ratio is -3.67. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to ADVIC.PA's ROE of +0.44%. Regarding short-term risk, ALPHA.PA is more volatile compared to ADVIC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check ADVIC.PA's competition here
ALPHA.PA vs VLAP.PA Comparison April 2026
ALPHA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPHA.PA stands at 1.2K. In comparison, VLAP.PA has a market cap of 0. Regarding current trading prices, ALPHA.PA is priced at €0.00, while VLAP.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPHA.PA currently has a P/E ratio of -0.00, whereas VLAP.PA's P/E ratio is -0.10. In terms of profitability, ALPHA.PA's ROE is +0.83%, compared to VLAP.PA's ROE of -0.75%. Regarding short-term risk, ALPHA.PA is more volatile compared to VLAP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPHA.PA.Check VLAP.PA's competition here